New insights into the treatment of CTD-ILD

[1]  R. Porcher,et al.  Methotrexate and rheumatoid arthritis associated interstitial lung disease , 2020, European Respiratory Journal.

[2]  J. Nolla,et al.  A prospective study of lung disease in a cohort of early rheumatoid arthritis patients , 2020, Scientific Reports.

[3]  J. Goldin,et al.  Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2020, The Lancet. Respiratory medicine.

[4]  N. Seersholm,et al.  Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. , 2020, Rheumatology.

[5]  K. Brown,et al.  Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. , 2020, The Lancet. Respiratory medicine.

[6]  Ran Liu,et al.  A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease , 2019, Clinical Rheumatology.

[7]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[8]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[9]  M. Baron,et al.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) , 2017, Annals of the rheumatic diseases.

[10]  M. Mejía,et al.  Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis , 2017, Clinical Rheumatology.